Kalpit Patel
Stock Analyst at B. Riley Securities
(0.98)
# 3,544
Out of 4,793 analysts
55
Total ratings
27.5%
Success rate
-13.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Initiates: Buy | $37 | $16.42 | +125.33% | 1 | Mar 20, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $24 | $17.24 | +39.21% | 6 | Mar 5, 2025 | |
| GERN Geron | Maintains: Buy | $5.5 → $3.5 | $1.38 | +153.62% | 3 | Feb 18, 2025 | |
| VSTM Verastem | Maintains: Buy | $7 → $9 | $5.16 | +74.42% | 4 | Jan 31, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $10 | $3.44 | +190.70% | 1 | Jan 30, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Neutral | $28 → $17 | $6.89 | +146.73% | 6 | Dec 13, 2024 | |
| PDSB PDS Biotechnology | Maintains: Buy | $9 → $7 | $0.95 | +636.76% | 5 | Nov 25, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $85 → $40 | $5.02 | +696.81% | 2 | Sep 20, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Neutral | $31 → $36 | $22.07 | +63.12% | 2 | Jul 9, 2024 | |
| OVID Ovid Therapeutics | Maintains: Buy | $9 → $3 | $0.28 | +965.34% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $11.99 | +66.81% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 → $1 | $0.21 | +365.98% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $7.19 | -16.55% | 5 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $11.25 | +220.00% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $9 → $3 | $0.15 | +1,885.44% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $1.44 | +1,150.00% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.60 | +212.50% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $120 | $0.61 | +19,731.43% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $8.41 | +1,089.06% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $5.88 | +1,175.51% | 2 | Sep 3, 2021 |
ArriVent BioPharma
Mar 20, 2025
Initiates: Buy
Price Target: $37
Current: $16.42
Upside: +125.33%
Rigel Pharmaceuticals
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $17.24
Upside: +39.21%
Geron
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.38
Upside: +153.62%
Verastem
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $5.16
Upside: +74.42%
Foghorn Therapeutics
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $3.44
Upside: +190.70%
Bicycle Therapeutics
Dec 13, 2024
Maintains: Neutral
Price Target: $28 → $17
Current: $6.89
Upside: +146.73%
PDS Biotechnology
Nov 25, 2024
Maintains: Buy
Price Target: $9 → $7
Current: $0.95
Upside: +636.76%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $5.02
Upside: +696.81%
Kymera Therapeutics
Jul 9, 2024
Maintains: Neutral
Price Target: $31 → $36
Current: $22.07
Upside: +63.12%
Ovid Therapeutics
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $0.28
Upside: +965.34%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $11.99
Upside: +66.81%
Dec 12, 2023
Downgrades: Neutral
Price Target: $3 → $1
Current: $0.21
Upside: +365.98%
Sep 7, 2023
Reiterates: Buy
Price Target: $6
Current: $7.19
Upside: -16.55%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $11.25
Upside: +220.00%
Nov 11, 2022
Downgrades: Neutral
Price Target: $9 → $3
Current: $0.15
Upside: +1,885.44%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $1.44
Upside: +1,150.00%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $1.60
Upside: +212.50%
Jun 7, 2022
Maintains: Buy
Price Target: $240 → $120
Current: $0.61
Upside: +19,731.43%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $8.41
Upside: +1,089.06%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $5.88
Upside: +1,175.51%